semaglutide vs tirzepatide chart vs retatrutide: the complete three-way comparison semaglutide plan vs tirzepatide plan

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]

As with any prescription medication, semaglutide may involve risks and side effects

Zealthy also advocated for me and successfully got my prescription covered by insurance, which was an absolute lifesaver

Steady use and regular follow-up visits support the best outcomes

[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Bkdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW